Compass Therapeutics, Inc.
CMPX
$5.26
-$0.06-1.13%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 22.12% | -17.54% | -1.48% | 51.23% | 19.18% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.54% | 29.23% | 32.53% | 40.69% | 7.67% |
| Operating Income | -8.54% | -29.23% | -40.02% | -40.69% | -7.67% |
| Income Before Tax | -4.54% | -36.05% | -52.04% | -54.19% | -12.06% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.54% | -36.05% | -52.04% | -54.19% | -12.06% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.54% | -36.05% | -52.04% | -54.19% | -12.06% |
| EBIT | -8.54% | -29.23% | -40.02% | -40.69% | -7.67% |
| EBITDA | -9.36% | -30.61% | -40.78% | -41.30% | -7.89% |
| EPS Basic | 22.73% | -10.89% | -51.37% | -52.28% | 0.00% |
| Normalized Basic EPS | 22.82% | -10.92% | -51.35% | -52.23% | 0.00% |
| EPS Diluted | 22.73% | -10.89% | -51.37% | -52.28% | 0.00% |
| Normalized Diluted EPS | 22.82% | -10.92% | -51.35% | -52.23% | 0.00% |
| Average Basic Shares Outstanding | 35.29% | 22.67% | 0.50% | 1.19% | 12.03% |
| Average Diluted Shares Outstanding | 35.29% | 22.67% | 0.50% | 1.19% | 12.03% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |